Patent intelligence · US
US 10167292
Benzodiazepines as bromodomain inhibitors
Benzodiazepines as bromodomain inhibitors
Patent details — US 10167292
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 1, 2019
- Expiration
- Dec 27, 2038
- Applicant
- Catalyst Therapeutics Pty Ltd.
- Claims
- 20
- CPC classes
- A61P, A61P29/00, A61P35/00, A61P37/02
Quick answer
US 10167292 (Benzodiazepines as bromodomain inhibitors) is held by Catalyst Therapeutics Pty Ltd.. Status: granted. Granted Jan 1, 2019. Expires Dec 27, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Catalyst Therapeutics Pty Ltd.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61P, A61P29/00, A61P35/00, A61P37/02, A61P43/00
More from Catalyst Therapeutics Pty Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 11806421
Porous-cellulose particles and production method thereof, and cosmetic
granted -
US 11701307
Organic-inorganic composite particles, manufacturing method therefor, and cosmetic
granted -
US 11491212
Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
granted -
US 11401513
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
granted -
US 11384062
Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
granted -
US 11266724
Modified factor VII polypeptides for subcutaneous administration and on-demand treatment
granted -
US 11203749
Factor VII polypeptides that are modified and uses thereof
granted -
US 11020326
Hollow particles and cosmetic
granted
Frequently asked questions
What is US patent 10167292?
US 10167292 (Benzodiazepines as bromodomain inhibitors) is held by Catalyst Therapeutics Pty Ltd.. Status: granted. Granted Jan 1, 2019. Expires Dec 27, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10167292?
Catalyst Therapeutics Pty Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 61 pharmaceutical patents for this assignee.
When does US 10167292 expire?
Our index shows an expiration date of Dec 27, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.